Business
Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer
Strategic promotion underscores commitment to commercial growth across Ocular portfolio BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix,
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":"Strategic promotion underscores commitment to commercial growth across Ocular portfolio\nBEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Steve Meyers as Chief Commercial Officer. “As we continue our commitment to advancing our drug portfolio in order to enhance the quality of life for patients, I am thrilled to announce the promotion of Steve Meyers to the role of Chief Commercial Officer,” said Antony Mattessich, CEO of Ocular Therapeutix. “Steve has consistently demonstrated exceptional leadership, strategic vision and a deep understanding of our mission. With his expertise and dedication, I am confident he will play a pivotal role in driving Ocular’s commercial efforts forward.” “I am truly honored by this opportunity to serve as Chief Commercial Officer,\" said Steve Meyers. “Over the past two years, I’ve been inspired by our commitment to develop transformational treatments to enhance people’s vision and quality of life. I’m eager to continue driving innovation and ultimately making a meaningful difference for patients and shareholders alike.” Mr. Meyers has over 20 years of commercial experience, including several buy and bill, specialty pharmacy and innovative technology product launches in highly competitive markets. Mr. Meyers served in other commercial capacities at leading biotechnology organizations including Regeneron, AbbVie, and Procter & Gamble. Prior to joining Ocular, Mr. Meyers served as Vice President of Sales at Flexion Therapeutics in the orthopedic space. Mr. Meyers holds a B.S. from Louisiana State University in Cardiopulmonary Science. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology ELUTYX™. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s ...